Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
Heart failure is a common complication in patients with diabetes, and people with both conditions present a worse prognosis. Sodium– glucose cotransporter 2 inhibitors (SGLT2Is) increase urinary glucose excretion, improving glycaemic control. In type 2 diabetes (T2D), some SGLT2Is reduce major cardi...
Guardado en:
Autor principal: | Juan Tamargo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Radcliffe Medical Media
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f82de07dc0f24218a4e62e82fdcb57e0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Corrigendum to: Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
por: Juan Tamargo
Publicado: (2019) -
Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
por: Muhammad Shahzeb Khan, et al.
Publicado: (2019) -
Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs
por: Thomas A Zelniker, et al.
Publicado: (2019) -
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
por: Giuseppe Rosano, et al.
Publicado: (2020) -
The Future of Telemedicine in the Management of Heart Failure Patients
por: José Silva-Cardoso, et al.
Publicado: (2021)